Never before have retail investors been more important to the prospects of small-cap public companies both to drive their businesses and their share prices through the use of social platforms. Let’s leave aside the recent exceptional case of GameStop (GME). But look what retail did to possibly save AMC (ticker: AMC). Incredible. As for small-caps like Chromadex (CDXC) (Nicotinamide Riboside or NR), its management undoubtedly realizes that their vocal community of early adopters (many of whom are also retail shareholders) have played a significant role in driving sales through “Word of Mouth” by sharing their experiences online and encouraging others to give NR a try. Rarely do you see such an active community take daily to Facebook, Reddit, Twitter and even Seeking Alpha (Disclosure) to spread word of the merits of a consumer product. This community represents a remarkable asset. As a result, Chromadex management has agreed to consider community questions for their upcoming March 10th earnings call. While management is obviously limited in what they can say, let’s use this opportunity to tell them what’s on our minds in the comments section below. And, of course, we’ll also enjoy the added benefit of hearing what’s on the minds of other smart investors, scientists, and consumers who are as interested as we are in the future of Nicotinamide Riboside “NR” (FAQs) (Reviews).
Recent Press Releases from Chromadex (ticker: CDXC):
New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function (10/8/20)
Celltrient™ Cellular Energy Products Featuring Tru Niagen® Launch in US (10/14/20)
ChromaDex Announces $25 Million Private Placement of Common Stock (2/22/21)
And….
RaisingNAD’s “10 Most Popular Posts” HERE.
RELATED:
- FAQs on taking NAD boosting vitamin supplement Nicotinamide Riboside (NR) can be found HERE.
- NR supplementation may have helped sufferers of these diseases & conditions (Consumer Reviews)
FOLLOW us on Twitter @RaisingNAD
William H Walker
First question should be “how did you manage to keep a successful Phase 3 coronavirus trial out of the media?”
Every health and fitness blogger on the planet should be talking about the Scandi Bio result.
Ezra
Thanks for doing this. On previous earnings calls you’ve referred to working on other NAD precursors. Anything more you can tell us about that? Thanks.
Milarepa
1. What upcoming studies is the company most excited about?
2. Is Nestle likely to expand into pet food or baby formula in 2021?
3. There have been a number of changes on the leadership team — what should we think about those?
4. Is a United States bricks-and-mortar distribution agreement likely in 2021?
5. What will be the greatest revenue growth driver in 2021?
Ig
1) is ScandiBio’s phase 3 covid result significant enough that it could open up a new revenue stream for NR? If yes, when?
2) is ScandiBio’s phase 2 NAFLD result significant enough that it could open up a new revenue stream for NR? If yes, when?
3) do you foresee the cost to produce NR as coming down anytime soon and would you pass those savings on to the consumer?
4) can you share what is the latest progress on stabilizing NR in liquids?
5) is there any NR clinical data that’s stuck in the peer review process? If yes, can you share how many studies are in this state?
Jeff Gilligan
1. Are there plans to seek FDA approval based on the results of the Scandibio’s Phase 3 COVID-19 trial?
2. Whether or not FDA approval is sought, are there plans to make the results known to the general public or to health care providers?
3. Are any trials planned for NR’s use regarding other viruses?
4. Can you estimate when the Scandibio’s fatty liver Phase 3 trial results will be known?
5. Has the Watson’s group made plans for over-the-counter sales in the EU?
6. Where does Chromadex stand in regard to over-the-counter approval in the People’s Republic of China, Taiwan, Japan, and South Korea?
Dave Crouse
Are there any discussions with food companies about using NR for general fortification purposes? What price point would make this a reality?
Can we expect NR to be used in any type of livestock feed? If so, what is the timeline?
Besides ScandiBio, have any other pharmaceutical companies contacted you about including NR in some type of drug cocktail?
Michael
1. Can you give us a progress update with specific details regarding China blue hat approval?
2. We recently saw a successful Kansas State NR chicken muscle study that was part of the ChromaDex CERP. If IP is generated from this study will ChromaDex be first in line to license it?
3. Is there any more clarity as to whether or not Tru Niagen beauty might be available in the US?
4. Have any foreign governments contacted ChromaDex regarding the purchase of NR in light of the Scandibio Phase 3 Covid results?
Michael
5. Do you have plans to put Tru Niagen in US brick and mortar stores (Whole Foods for example)?
stefan_001
What are your thoughts on improving the structure and transparency of your R&D and product pipeline now that you attracted a further 25M financing? It would better allow for the financial community to value the potential and assets of the company. The focus will also allow to build out the goto market for Niagen, currently the approach seems somewhat scattershot. Let me elaborate:
– will you establish a pharmaceutical / drug program (with partners) around NRH, on which you have solid and long running IPR?
– will you create research, partnering and goto market programs for the use of Niagen for the dominant ailments of aging? People tend to seek point solutions.
stefan_001
In your latest online investor presentation you list areas that NR is showing improvement / usefull benefits in various research programs. However it seems your online business is not using these results in the position Niagen with keywords for consumer searches. Can you elaborate on the plans to develop the online commerce platform?
Bob
This clinical trial shows April 2019 as “completed”. Any idea when these results will be published? The sponsor of this study is ChromaDex, Inc. This is a double-blind, randomized, crossover study to investigate the effects of 300 mg/d and 1000 mg/d TRU NIAGEN (nicotinamide riboside) compared to a placebo control on cognitive function, mood and sleep in men and women over 55 years of age. The trial is managed by Midwest Center for Metabolic and Cardiovascular Research.
David
What is the expected primary used of the placement funds? If it’s for trials, what is the most likely trial and the approximate cost.
MIlarepa
Can you please comment on some of the newer patents that ChromaDex has recently been granted or licensed, and their significance?
Milarepa
Can you comment on any of the more recent additions to ChromaDex’s portfolio of patents owned or licensed, and their significance (e.g., Patent 10,934,322)?
-
Can you comment on the work of Dr Felding’s lab and the status of that research? What is the target opportunity for that project? Thank you very much for taking time to review these questions.
Josh
Will the “next generation” precursors that Chromadex has be offered as drugs or supplements ?
Aaaa
Recently have noticed out of stock notices on several sites, especially in the EU. Is this caused by increase demand or temporary supply chain disruption? If demand, can you give any insights into the increase in Q1 so far? If supply chain, what has been done to resolve this to accommodate new customers created by recently released studies?
Richard
How is the SuperDrug trial doing? Will more SuperDrug locations outside the 200 or so test stores start selling Tru Niagen? Are they ready to start running tests in other EU countries like Germany where Watson’s has a very large chain called Rossman’s? After the latest covid study, would Watson’s start selling Tru Niagen in Turkey? Close to selling in any other countries?
Also, are we getting closer to having major athletes or professional sports teams coming forward and discussing their Tru Niagen with the media?